Cargando…

Current appraisal of single inhaler triple therapy in COPD

A single inhaler containing inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA) is a more convenient way of delivering triple therapy in patients with COPD. Single triple therapy has been shown to be superior at reducing exacerbations and improving q...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipworth, Brian, Kuo, Chris RuiWen, Jabbal, Sunny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167973/ https://www.ncbi.nlm.nih.gov/pubmed/30319248 http://dx.doi.org/10.2147/COPD.S177333

Ejemplares similares

I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements
por: Kuo, Chris RuiWen, et al.
Publicado: (2019)

Inhaled Corticosteroids and COVID-19
por: Lipworth, Brian, et al.
Publicado: (2020)

Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD
por: Jabbal, Sunny, et al.
Publicado: (2017)

Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on
por: Lipworth, Brian, et al.
Publicado: (2020)

Type 2 Asthma Inflammation and COVID-19: A Double Edged Sword
por: Lipworth, Brian, et al.
Publicado: (2021)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
por: Resta, Emanuela, et al.
Publicado: (2022)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Resistance Heterogeneity and Small Airway Asthma Phenotype
por: Lipworth, Brian, et al.
Publicado: (2019)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection
por: Lipworth, Brian, et al.
Publicado: (2020)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

COVID-19: Start with the nose
por: Lipworth, Brian, et al.
Publicado: (2020)

Sex Hormones and Asthma: Don’t Forget Progesterone
por: Lipworth, Brian, et al.
Publicado: (2020)

Does unified allergic airway disease impact on lung function and type 2 biomarkers?
por: Kuo, Chris RuiWen, et al.
Publicado: (2019)

Don’t Forget about Facilitatory Effects of Corticosteroids on β(2)-Adrenoceptors in Acute Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

Is Gly16Arg β(2) Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?
por: Jabbal, Sunny, et al.
Publicado: (2016)

Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD
por: Manoharan, Arvind, et al.
Publicado: (2016)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Triple therapy in COPD: understanding the data
por: Suissa, Samy
Publicado: (2023)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
por: Kim, Sae Ahm, et al.
Publicado: (2016)

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
por: Kiff, Chris, et al.
Publicado: (2018)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Erratum: Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
Publicado: (2016)

Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine‐induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler
por: Singh, Dave, et al.
Publicado: (2019)

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients
por: López-Campos, José Luis, et al.
Publicado: (2020)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
por: Jiang, Yixuan, et al.
Publicado: (2021)

PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
por: Criner, Gerard, et al.
Publicado: (2023)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
por: Bansal, Sandeep, et al.
Publicado: (2021)

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
por: Malerba, Mario, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lq2bbqrsdegh87cs8f9ddo7fqk